1.60 I-PREDICT, Flawed Phase I Trials, & the Cost of Drugs with Dr. Daniel Hartung

Plenary Session

English - May 09, 2019 23:05 - 1 hour - 89.7 MB - ★★★★★ - 732 ratings
Science Health & Fitness Medicine medicine oncology health policy Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: 1.59 BONUS! Should Evidence Come with an Expiration Date? with Palmer Greene

Next Episode: 1.61 Postpublication Metrics of RCTs, PCP Appointment Time, Bortezomib, & Dr. Christopher Booth

We revisit I-PREDICT, discuss the "Imputability of Adverse Events to Anticancer Drugs" (a letter published recently in the New England Journal of Medicine), and interview Dr. Daniel Hartung of Oregon State University's College of Pharmacy on his vast knowledge of the cost of drugs, specifically addressing Acthar gel and multiple sclerosis drugs.

Imputability of Adverse Events: doi.org/10.1056/NEJMc1900053

Back us on Patreon! www.patreon.com/plenarysession